Advertisement

Topics

SYNT:EM Company Profile

06:52 EDT 19th June 2018 | BioPortfolio

Synt:em is a private French biopharmaceutical company that is focused on the discovery and development of novel drugs that address unmet medical needs in cancer, pain management and diseases of the Central Nervous System.
Synt:em’s strategy is to take advantage of its complementary and proprietary technology platforms Pep:trans™ and Acti:map™ to develop an internal pipeline of drug candidates for the treatment of CNS disorders. In addition, Synt:em will continue establishing strong partnerships with Pharma and Biotech companies based on its Pep:trans™ and Acti:map™ technologies.
Pep:trans™ is a unique way to modify the pharmacological behaviour of compounds ranging from small molecules to peptides or proteins, by helping them to reach their target across complex biological membranes. With Pep:trans™, Synt:em is able to address the problem of delivering therapeutic molecules to the brain through the Blood Brain Barrier. In addition, the technology is used to improve the uptake of therapeutics into cells so that they are able to interact optimally with intracellular targets.

Location

Parc ScientifiqueGeorges Besse
Nîmes
Cedex 1
30035
France

Contact

Phone: 33 (0)466 048 666
Fax: 33 (0)466 048 667
Email: syntem@syntem.com


News Articles [2 Associated News Articles listed on BioPortfolio]

This Morning's Research Reports on IT Services Stocks -- Gartner, International Business ...

WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on IT, IBM, SABR, and SYNT which can Read more...

A new formula for creating chemical reactions - with carbs

A wide range of drugs and biochemical probes - everything from antibiotics to Alzheimer's disease biomarkers - rely on natural or synthetic compounds that aid a reaction by adding carbohydrates. It's ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

SYNT:EM

Synt:em is a private French biopharmaceutical company that is focused on the discovery and development of novel drugs that address unmet medical needs in cancer, pain management and diseases of the C...

More Information about "SYNT:EM" on BioPortfolio

We have published hundreds of SYNT:EM news stories on BioPortfolio along with dozens of SYNT:EM Clinical Trials and PubMed Articles about SYNT:EM for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SYNT:EM Companies in our database. You can also find out about relevant SYNT:EM Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record